Use of fluoroquinolones as prophylactic agents in patients with neutropenia

被引:20
|
作者
Patrick, CC [1 ]
机构
[1] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
关键词
fluoroquinolones; selective decontamination; neutropenia; bacterial infections;
D O I
10.1097/00006454-199701000-00038
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The use of fluorinated quinolone antibiotics to selectively decontaminate the gastrointestinal tract is a reasonable alternative to prevent infection in neutropenic patients. The fluoroquinolones represent ideal antibiotics with which to achieve the principles of selective decontamination by allowing colonization of anaerobes to inhibit the adherence, colonization and proliferation of potentially pathogenic aerobic flora. Objective. This report describes the prophylactic use of fluoroquinolones in neutropenic patients. Results. The majority of studies of fluoroquinolone prophylaxis in neutropenic patients have shown a reduction in documented Gram-negative bacterial infections. However, Gram-positive infections, particularly those with viridans streptococci, present a major impediment to the use of single agent prophylaxis with a quinolone. Conclusion. Prophylaxis with fluoroquinolones in neutropenic patients was found to be advantageous, but it must be balanced against the risk of Gram-positive infections and the potential for antibiotic resistance.
引用
收藏
页码:135 / 139
页数:5
相关论文
共 50 条
  • [21] A review of clinical trials with fluoroquinolones with an emphasis on new agents
    Blondeau, JM
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (02) : 383 - 413
  • [22] Heath Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia
    Restrepo, Marcos I.
    Frei, Christopher R.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 : S39 - S46
  • [23] Fluoroquinolones in ophthalmology: indications and current use
    Chiquet, C.
    Labetoulle, M.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2008, 31 (08): : 803 - 808
  • [24] Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
    Tamaki, Sawako
    Ishikawa, Hideki
    Suzuki, Koichi
    Kimura, Yasuaki
    Maemoto, Ryo
    Abe, Iku
    Endo, Yuhei
    Kakizawa, Nao
    Watanabe, Fumiaki
    Futsuhara, Kazushige
    Saito, Masaaki
    Tsujinaka, Shingo
    Miyakura, Yasuyuki
    Rikiyama, Toshiki
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (05)
  • [25] Cautious use of fluoroquinolones in respiratory infections
    Bouros, Demosthenes
    PNEUMON, 2016, 29 (03) : 191 - +
  • [26] Risks associated with the therapeutic use of fluoroquinolones
    Stahlmann, Ralf
    Lode, Hartmut M.
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (04) : 497 - 505
  • [27] Agents under investigation for the treatment and prevention of neutropenia
    Huston, Alissa
    Lyman, Gary H.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (11) : 1831 - 1840
  • [28] Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy
    Rajan, Suja S.
    Lyman, Gary H.
    Stearns, Sally C.
    Carpenter, William R.
    MEDICAL CARE, 2011, 49 (07) : 649 - 657
  • [29] Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones
    Mensa, J
    Trilla, A
    CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 : 42 - 54
  • [30] The Use of Antimicrobial Agents in Children With Fever During Chemotherapy-induced Neutropenia The Importance of Risk Stratification
    Palazzi, Debra L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (10) : 887 - 890